WHC is still in active development. Read this to understand our approach.
depiction of KQPKPCNLIDLUMF-UHFFFAOYSA-N.svg
tripsit

secobarbital

Verificar en tripsit

psychonaut

Secobarbital

Verificar en psychonaut

isomerdesign

Secobarbital

Verificar en isomerdesign

pubchem

Secobarbital

Verificar en pubchem

druglab

Secobarbital

Verificar en druglab

drugmap

Secobarbital

Verificar en drugmap

wiki

Secobarbital

Verificar en wiki

Data

InChI: InChI=1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)

Sinónimos: 5-ALLYL-5-(1-METHYLBUTYL)BARBITURIC ACID,Quinalbarbitone, Seotal,Meballymalum,Secobarbital, United States Pharmacopeia (USP) Reference Standard,5-Allyl-5-(1-methylbutyl)barbiturate, 5-Allyl-5-(1-methylbutyl)barbiturate,Secobarbital solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material,Hypotrol, Hypotrol,2,4,6(1H,3H,5H)-Pyrimidinitrione, 5-(1-methylbutyl)-5-(2-propenyl)-,EINECS 200-982-2,Secobarbital,(RS)-Secobarbital,5-(pentan-2-yl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione,Barbituric acid, 5-allyl-5-(1-methylbutyl)-,Secobarbital cii,5-Allyl-5-(1-methylbutyl)malonylurea,Secobarbitale,Quinalbarbital,SECOBARBITAL [USP IMPURITY], Secobarbital solution, (+-)-Secobarbital, Secobarbitone, 5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione,5-allyl-5-(1-methylbutyl)-barbituric acid,Meballymal,HSDB 3182,BRN 0225330, Seconal (TN), Secobarbitalum,Q414788,5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione,Secobarbital solution, 1.0 mg/mL in methanol, analytical standard, for drug analysis, 5-(pentan-2-yl)-5-(prop-2-en-1-yl)-pyrimidine-2,4,6(1H,3H,5H)-trione,(+-)-5-Allyl-5-(1-methylbutyl)-barbituric acid, Quinalbarbitone, Secobarbital suppository dosage form,UNII-1P7H87IN75,BARBITURIC ACID, 5-ALLYL-5-(1-METHYLBUTYL)-, (+-)-,5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione, Pramil,Evronal, 5-Allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione,Seconal (TN), 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, (+-)-(9CI), Quinalbarbital,2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, (+-)-,Somosal,SECOBARBITAL [USP-RS],GTPL7615,secobarbital,CHEBI:9073, Meballymalum, (+-)-5-Allyl-5-(1-methylbutyl)-barbituric acid,Secobarbital 0.1 mg/ml in Methanol,Hyptran (Salt/Mix), 5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione,DTXSID6044145,(+/-)-Secobarbital,5-Allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione,Secobarbital, analytical standard,Secobarbitalum [INN-Latin],NCGC00247712-01,Secobarbital suppository dosage form [DEA No. 2316],Hyptran,2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-,Trisomnin (Salt/Mix),5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione,Sodium secobarbital,Sodium quinalbarbitone,Secobarbitale [DCIT], Secobarbitale, Secobarbitalum [INN-Latin], Secobarbital [USAN:INN],CHEMBL447,(.+/-.))-Secobarbital,5-(pentan-2-yl)-5-(prop-2-en-1-yl)-pyrimidine-2,4,6(1H,3H,5H)-trione, Hyptran, Seconal,Imesonal (Salt/Mix), Secobarbitale [DCIT], Somosal,D00430,1P7H87IN75,SECOBARBITAL [INN],SCHEMBL80734,Secobarbital sodium free acid,Secobarbital 1.0 mg/ml in Methanol,Secobarbital (USP/INN),76-73-3,5-24-09-00235 (Beilstein Handbook Reference),(+-)-Secobarbital,SECOBARBITAL [VANDF],Immenoctal (Salt/Mix), Evronal,5-(1-Methylbutyl)-5-(2-propen-1-yl)-2,4,6(1H,3H,5H)-pyrimidinetrione,Somatarax,DEA No. 2315,Secobarbitone,Secobarbital suppository dosage form,2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propen-1-yl)-,(+/-)-Quinalbarbitone,Secobarbitalum,Secobarbital [USP:INN],SECOBARBITAL SODIUM FREE ACID [MI],SECOBARBITAL [WHO-DD],Seconal,5-Pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione,29071-21-4,Barbosec,seconal,S0223,SECOBARBITAL [HSDB], 5-Allyl-5-(1-methylbutyl)malonylurea,5-ALLYL-5-(1-METHYLBUTYL)BARBITURIC ACID,DB00418,Immenox, 5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione,SECOBARBITAL [MART.],SCHEMBL11110602,2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-methylbutyl)-5-(2-propenyl)-, (+-)- (9CI), Meballymal

Estimated data

Solubilidad: -2.395 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 34.9% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.